Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.51), $1.14 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $410 million versus the consensus estimate of $410.82 million.

GUIDANCE:

Neurocrine Biosciences sees FY2023 revenue of $1.67-1.77 billion, versus the consensus of $1.81 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.